BioSpace4m
Adcendo Rides ADC Wave With $135M Series B
Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.
BioSpace21m
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
BioSpace3h
Trump Picks Vaccine Critic Weldon to Lead CDC, Makary for FDA Head
Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control ...
BioSpace10h
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy
With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...
BioSpace10h
Next-Gen ADCs Driving ‘Renaissance’ in Already Hot Oncology Drug Class
ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...
BioSpace10h
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...